article thumbnail

STAT+: Wegovy is among drugs set to be targeted in the next round of Medicare price negotiations, researchers say

STAT

The GLP-1 drug Wegovy tops the list of medications expected to be included in the next round of Medicare price negotiations, according to a paper in the Journal of Managed Care & Specialty Pharmacy.    Last month, Medicare officials unveiled prices for the first 10 drugs chosen for negotiation.

article thumbnail

Amber Specialty Pharmacy Selected to Dispense TZIELD™ (teplizumab), a Monoclonal Antibody Treatment to Delay Onset of Stage 3 Type 1 Diabetes in Patients Ages 8 Years and Older with Stage 2 Type 1 Diabetes

Amber

21, 2022) – Amber Specialty Pharmacy announces that it will begin dispensing TZIELD (teplizumab), an anti-CD3 monoclonal antibody, to delay Stage 3 Type 1 Diabetes (T1D) in patients ages 8 years and older with Stage 2 T1D. Read more about the pharmacy’s infusion service offerings here. OMAHA, Neb.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Rethinking Glucose Monitoring With AI and Nanomaterials

Pharma Marketing Network

By Max Kopp Diabetes care is entering a new era—yet even in 2025, continuous glucose monitors (CGMs) remain out of reach for millions. Despite a decade of innovation, current CGMs often fail to meet the needs of everyday people with type 2 diabetes, particularly those in under-resourced or underserved communities.

article thumbnail

Orsini Specialty Pharmacy Selected by Provention Bio as a Limited Distribution Partner for TZIELD

Orsini Pharmacy

Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, has been selected by Provention Bio, Inc. as a specialty pharmacy for TZIELD ® (teplizumab).

article thumbnail

Health System Specialty Pharmacies Impact Medication Adherence, Total Cost of Care

Pharmacy Times

HSSPs improve medication adherence and reduce total health care costs by directly managing medications for complex chronic conditions like cancer, diabetes, COPD and CHF.

article thumbnail

Specialty pharma’s next big opportunity: it’s time for patient access to adopt an open protocol

pharmaphorum

A similar inflection point now faces the specialty pharmaceutical industry. Along their journey, specialty pharma patients interact with a series of siloed institutions: clinics, specialty pharmacies, copay program vendors, patient assistance programs, nurses, etc. About the author.

HIPAA 98
article thumbnail

Expanding Pneumococcal Vaccinations to Healthy Adults Aged 50 to 64 Years Offers Significant Health, Economic Benefits

Pharmacy Times

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)